Pre-IND Study of Pz-1, a dual pan-RET/VEGFR2 inhibitor for the Treatment of RET-driven Disease Abstract...
Synactix is derived from synergy and action. Synactix is founded on the principle that the 'one-drug, one-target' approach is inadequate to treat many types of human disease. We have established a robust targeted strategy focused on single-agent polypharmacology, or ‘one-drug, many targets’. Single-agent targeting of multiple pathways in human disease is the future of modern medicine
The Synactix strategy is to condense multi-drug therapies into single-agent, multi-targeted precision medicine treatments. We call this approach Single-Agent Polypharmacology or SAP. The Synactix lead project has produced a dual targeted kinase inhibitor for treatments of rare cancers. Although there are several multi-kinase inhibitors in clinical use today, activity profiles of these inhibitors have not been optimized and can lead to off-target toxicities. Using SAP, Synactix has identified the first balanced, multi-targeted single-agent strategically engineered to both starve and kill malignant tumor growth.
Our strategy is to develop single-agent treatment modalities that effectively shut down multiple promoters of disease. These treatment modalities will have the same efficacy as treating with multiple drugs, however, smarter design minimizes off target effects and balances the effect of treatment to focus in on disease driving mechanisms.Read More
Win the battle and the war
Polypharmacology is the future of modern medicine.
Low-hanging drug targets have been heavily exploited and potential for target breakthroughs is rare. To excel in a competitive market,
Synactix uses a propriety technology to generate 'smart-drugs' that are capable of shutting down multiple pathways of human disease.
Instead of drug-repurposing, Synactix has established the concept of 'target- repurposing'.
Synactix identifies drug targets that display pathway cooperation in a variety of disease states.
Synactix then engineers highly advanced, single-agent drug candidates to shut down these targets in a balanced fashion.
Synactix is innovating the future of precision medicine.
follow our news
The inhibitory powers of a next-generation inhibitor were carefully balanced so that it is equally potent on the RET kinase and...
University of Arizona startup company Synactix Pharmaceuticals Inc. has licensed a novel cancer treatment technology developed...
© 2016. All Rights reserved by Synactix Pharmaceuticals, Inc. | Designed by CityX